NEW YORK (GenomeWeb) – Somalogic and DeCode Genetics announced today that they are collaborating on a proteomic analysis of up to 40,000 of DeCode's patient samples.
The analysis will use Somalogic's SomaScan platform, which measures the levels of 5,000 proteins using the company's Somamer affinity reagents. According to the firms, Reykjavik-based DeCode will use the data gathered through this analysis for drug discovery and development work, while Boulder, Colorado-based Somalogic will use the findings to develop clinical applications of the SomaScan platform.
"I am excited to see what deep proteomic analysis will add to what we already know about human health based on our study of genetics," Kári Stefánsson, founder and CEO of DeCode said in a statement. "SomaLogic's ability to measure thousands of proteins brings a whole new dimension to our efforts, and we look forward to seeing the results."
"This collaboration with DeCode gives us an exciting opportunity to work with one of the most highly characterized and understood datasets in the world, as well as with world-class genomic and pharmaceutical scientists," Stephen Williams, chief medical officer at SomaLogic, said in a statement. "We are undertaking together the largest protein study ever performed — over 200 million individual protein measurements — to gain substantial new knowledge about normal and disease biology across many common and rare conditions."
Financial and other terms of the agreement were not disclosed.